Results 221 to 230 of about 93,323 (254)

Immune interplay between sepsis and haematological malignancies. [PDF]

Intensive Care Med Exp
Pons S, Grosset M, Touze E, Zafrani L.
europepmc   +1 more source

Cutaneous Hematologic Neoplasms in Children: Overview and Update. [PDF]

Dermatopathology (Basel)
Drabent P, Welfringer A, Gru AA, Molina TJ, Fraitag S.   +4 more
europepmc   +1 more source

Deficiency of Setd2 in mesenchymal stem cells facilitates the progression of myelodysplastic syndrome to leukemia. [PDF]

Mol Med
Wang RJ, Li ZJ, Chen BY, Guo J, Tao Y, Li HP, Fei MY, Chang BH, Zhao MY, Shi L, Zhao SD, Zhang Z, Su JY, Song LX, He Q, Wu D, Wu LY, Zhang JY, Zong LJ, Sun XJ, Zhao YS, Wang L, Chang CK.   +22 more
europepmc   +1 more source

Introduction to the Review Series. Clonal hematopoiesis review series - from biology to clinical management. [PDF]

Haematologica
Piric AA, Schimmer AD.
europepmc   +1 more source

Hematologic malignancies in pediatric patients with RUNX1-familial platelet disorder with associated myeloid malignancy. [PDF]

Blood Adv
Kajdic A, Deuitch NT, Bresciani E, Chong S, Craft K, Davis J, Bashtawi R, McReynolds LJ, Giri N, Young DJ, Liu PP.   +10 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Suppressing crucial oncogenes of leukemia initiator cells by major royal jelly protein 2 for mediating apoptosis in myeloid and lymphoid leukemia cells.

Food & Function, 2022
Relapse of leukemia and drug resistance are still the major obstacles to therapy due to leukemia-initiating stem/progenitor cells (LICs); thus, targeting them using safe compounds is crucial. Here, we evaluated the anti-leukemic effect of royal jelly (RJ)
Marwa M. Abu‐Serie, Noha H. Habashy
semanticscholar   +1 more source

A Phase 1 Study of the Oral CDK9 Inhibitor Voruciclib in Relapsed/Refractory (R/R) B-Cell Lymphoma (NHL) or Acute Myeloid Leukemia (AML)

Blood, 2023
Background: The anti-apoptotic protein Mcl-1 contributes to the pathophysiology of certain B-cell malignancies and AML, and dependence on Mcl-1 is associated with resistance to venetoclax.
M. Davids, Yesid Alvarado Valero, C. Diefenbach, Daniel N. Egan, S. Dinner, M. A. Al Malki, K. Begna, A. Kallam, S. Abedin, R. Cook, Nathalie Javidi-Sharifi, Edward C Dominguez, Lu Miao, R. Ghalie, Alexey Danilov   +14 more
semanticscholar   +1 more source

B-Lymphoid Blast Phase of Chronic Myeloid Leukemia: A Case Report and Review of the Literature

AJSP: reviews & reports, 2019
Chronic myeloid leukemia (CML) is a clonal hematopoietic stem cell disorder characterized by a reciprocal translocation, t(9;22) (q34.1;q11.2). This leads to fusion of the BCR and ABL1 genes, encoding an active tyrosine kinase that causes unregulated ...
A. Ware, L. Wake, P. Brown, Jonathan A. Webster, B. Smith, A. Duffield   +5 more
semanticscholar   +1 more source

Zinc finger protein 384 (ZNF384) impact on childhood mixed phenotype acute leukemia and B-cell precursor acute lymphoblastic leukemia

Leukemia and Lymphoma, 2022
B-cell precursor acute lymphoblastic leukemia (BCP-ALL) is a heterogeneous malignancy and consists of several genetic abnormalities. Some of these abnormalities are used in clinics for risk calculation and treatment decisions.
Tugce Sudutan, Y. Erbilgin, Ozden Hatırnaz Ng, S. Karaman, Z. Karakaş, Fulya Kucukcankurt, T. Celkan, Ç. Timur, G. Ozdemir, Şadan Hacısalihoğlu, S. A. Gelen, M. Sayitoglu   +11 more
semanticscholar   +1 more source

Systemic Multifunctional Nanovaccines for Potent Personalized Immunotherapy of Acute Myeloid Leukemia

Advances in Materials
Hematological malignancies (HM) like acute myeloid leukemia (AML) are often intractable. Cancer vaccines possibly inducing robust and broad anti‐tumor immune responses may be a promising treatment option for HM.
Peng Zhang, Tanzhen Wang, Guanhong Cui, Ruonan Ye, Wenjun Wan, Tianhui Liu, Yiran Zheng, Z. Zhong   +7 more
semanticscholar   +1 more source